Author
Listed:
- Vincent Ka Chun Yan
(The University of Hong Kong)
- Yu Yang
(The University of Hong Kong)
- Eric Yuk Fai Wan
(The University of Hong Kong
Hong Kong Science and Technology Park
The University of Hong Kong)
- Francisco Tsz Tsun Lai
(The University of Hong Kong
Hong Kong Science and Technology Park)
- Celine Sze Ling Chui
(Hong Kong Science and Technology Park
The University of Hong Kong
The University of Hong Kong)
- Xue Li
(The University of Hong Kong
Hong Kong Science and Technology Park
The University of Hong Kong)
- Carlos King Ho Wong
(The University of Hong Kong
Hong Kong Science and Technology Park
The University of Hong Kong)
- Ivan Fan Ngai Hung
(The University of Hong Kong)
- Chak Sing Lau
(The University of Hong Kong)
- Ian Chi Kei Wong
(The University of Hong Kong
Hong Kong Science and Technology Park
Macau University of Science and Technology
Aston University)
- Esther Wai Yin Chan
(The University of Hong Kong
Hong Kong Science and Technology Park
The University of Hong Kong-Shenzhen Hospital
The University of Hong Kong Shenzhen Institute of Research and Innovation)
Abstract
Background Immunocompromised individuals are at high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent severe or fatal coronavirus disease 2019 (COVID-19), yet they have suboptimal responses to mRNA and inactivated COVID-19 vaccines. The efficacy of tixagevimab–cilgavimab in reducing symptomatic SARS-CoV-2 infection was demonstrated in phase III clinical trials. Nevertheless, real-world data on the effectiveness and safety of tixagevimab–cilgavimab remain limited. Objective The aim was to evaluate the effectiveness and safety of tixagevimab–cilgavimab among immunocompromised individuals. Methods Adults who were immunocompromised or receiving immunosuppressive therapies were included in this target trial emulation using territory-wide electronic health records in Hong Kong. A sequential trial emulation approach was adopted to compare effectiveness and safety outcomes between individuals who received tixagevimab–cilgavimab and individuals who did not. Results A total of 746 tixagevimab–cilgavimab recipients and 2980 controls were included from 1 May 2022 to 30 November 2022. Tixagevimab–cilgavimab significantly reduced the risk of COVID-19 infection (hazard ratio [HR] 0.708, 95% confidence interval [CI] 0.527–0.951) during a median follow-up of 60 days. No significant difference was observed in the risk of COVID-19-related hospitalisation. Zero versus eight COVID-19 mortality cases and zero versus two severe COVID-19 cases were observed in tixagevimab–cilgavimab recipients and controls, respectively. Notably, significant risk reduction in COVID-19 infection was also observed among immunocompromised individuals who had been previously vaccinated with three or more doses of COVID-19 vaccine, or had no prior COVID-19 infection history. Conclusions Tixagevimab–cilgavimab was effective in reducing COVID-19 infection among immunocompromised patients during the Omicron wave. Findings were consistent among individuals who previously received three or more doses of COVID-19 vaccine, or had no previous history of COVID-19 infection.
Suggested Citation
Vincent Ka Chun Yan & Yu Yang & Eric Yuk Fai Wan & Francisco Tsz Tsun Lai & Celine Sze Ling Chui & Xue Li & Carlos King Ho Wong & Ivan Fan Ngai Hung & Chak Sing Lau & Ian Chi Kei Wong & Esther Wai Yin, 2024.
"Real-World Effectiveness and Safety of Tixagevimab–Cilgavimab: A Target Trial Emulation Study,"
Drug Safety, Springer, vol. 47(10), pages 1025-1037, October.
Handle:
RePEc:spr:drugsa:v:47:y:2024:i:10:d:10.1007_s40264-024-01450-4
DOI: 10.1007/s40264-024-01450-4
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:10:d:10.1007_s40264-024-01450-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.